AITLs have recurrent mutations in genes encoding TET2, IDH2 R172, and DNMT3A, with some mutations being identified in non-tumor cells of patients with AITL and even in some healthy donors; however, IDH2R172 and RHOAG17V mutations are confirmed to tumor cells; all these may help in targeted therapy and personalized therapeutical approaches [8,9,10,11,12]. This evidence concerns the gene DNMT3A and neoplasm.